Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canopy GrowthCGC -1.03%40 6-1 Month Momentum % is -18.27% as of Aug. 19, 2026. GuruFocus rates CGC with a GF Score™ of 40/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Canopy Growth ranks worse than 54.19% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-19), Canopy Growth's 6-1 Month Momentum % is -18.27%.
The industry rank for Canopy Growth's 6-1 Month Momentum % or its related term are showing as below:
CGC's 6-1 Month Momentum % is ranked worse than 54.19% of 1026
companies
in the Drug Manufacturers industry
Industry Median: -11.24
vs CGC: -18.27
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Canopy Growth 6-1 Month Momentum % Related Terms
CGC vs ZTS: 6-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth 6-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Canopy Growth's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (CGC) has a 6-1 Month Momentum % of -18.27% as of Aug. 19, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Canopy Growth and its competitors. According to the industry distribution chart, Canopy Growth ranks #556 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is Canopy Growth's 6-1 Month Momentum % too high?
Canopy Growth's current 6-1 Month Momentum % is -18.27%. Based on the distribution chart, Canopy Growth ranks #556 out of 1026 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Canopy Growth has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's 6-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #556 out of 1026 companies for 6-1 Month Momentum %. This places Canopy Growth in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Drug Manufacturers company?
A good 6-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Canopy Growth and its competitors. Canopy Growth's current 6-1 Month Momentum % is -18.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (CGC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.99 — trading 47.5% above its estimated fair value. The current 6-1 Month Momentum % is -18.27%. Canopy Growth's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Canopy Growth (CGC), the current 6-1 Month Momentum % is -18.27% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (CGC) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of $0.99 is trading 47.5% above its estimated GF Value™ of $0.67.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for CGC:
6-1 Month Momentum %: -18.27%
GF Value™: $0.67 vs. price of $0.99 (47.5% above fair value)
No single metric tells the full story. See the CGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
40GF Score
Get the complete analysis for CGC
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGC has been successfully added to your 
